| Literature DB >> 34769188 |
Magda Chalecka1, Adam Kazberuk1, Jerzy Palka1, Arkadiusz Surazynski1.
Abstract
Studies of cancer metabolism have focused on the production of energy and the interconversion of carbons between cell cycles. More recently, amino acid metabolism, especially non-essential amino acids (NEAAs), has been investigated, underlining their regulatory role. One of the important mediators in energy production and interconversion of carbons in the cell is Δ1-pyrroline-5-carboxylate (P5C)-the physiological intracellular intermediate of the interconversion of proline, ornithine, and glutamate. As a central component of these conversions, it links the tricarboxylic acid cycle (TCA), urea cycle (UC), and proline cycle (PC). P5C has a cyclic structure containing a tertiary nitrogen atom (N) and is in tautomeric equilibrium with the open-chain form of L-glutamate-γ-semialdehyde (GSAL). P5C is produced by P5C synthase (P5CS) from glutamate, and ornithine via ornithine δ-amino acid transferase (δOAT). It can also be converted to glutamate by P5C dehydrogenase (P5CDH). P5C is both a direct precursor of proline and a product of its degradation. The conversion of P5C to proline is catalyzed by P5C reductase (PYCR), while proline to P5C by proline dehydrogenase/oxidase (PRODH/POX). P5C-proline-P5C interconversion forms a functional redox couple. Their transformations are accompanied by the transfer of a reducing-oxidizing potential, that affect the NADP+/NADPH ratio and a wide variety of processes, e.g., the synthesis of phosphoribosyl pyrophosphate (PRPP), and purine ribonucleotides, which are crucial for DNA synthesis. This review focuses on the metabolism of P5C in the cell as an interconversion mediator of proline, glutamate, and ornithine and its role in the regulation of survival and death with particular emphasis on the metabolic context.Entities:
Keywords: NADPH; P5C dehydrogenase; P5C reductase; P5C synthase; PRODH/POX; ornithine aminotransferase; proline cycle; redox signaling; Δ1-pyrroline-5-carboxylate
Mesh:
Substances:
Year: 2021 PMID: 34769188 PMCID: PMC8584052 DOI: 10.3390/ijms222111763
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The metabolic pathways of P5C—physiological intracellular intermediate of the interconversion of proline, ornithine, and glutamate. Acetyl-CoA—acetyl coenzyme A, ATP—adenosine triphosphate, α-KG—α-ketoglutarate, Glu—glutamate, GSAL—L-glutamate-γ-semialdehyde, METC—mitochondrial electron transport chain, NAD+—oxidized form of nicotinamide adenine dinucleotide, NADH—reduced form of nicotinamide adenine dinucleotide, NADP+ –oxidized form of nicotinamide adenine dinucleotide phosphate, NADPH—reduced form of nicotinamide adenine dinucleotide phosphate, ORN—ornithine, P5C—Δ1-pyrroline-5-carboxylate, P5CDH—P5C dehydrogenase, P5CS—P5C synthase, PAT1—proton-coupled amino acid transporter 1, PRODH/POX—proline dehydrogenase/oxidase, PROT—L-proline transporter PROT, PYCR1/2/L—P5C reductase 1/2/L, ROS—reactive oxygen species, SIT1—sodium/imino-acid transporter 1, SNAT1/2—sodium-coupled neutral amino acid transporter 1/2, TCA cycle—tricarboxylic acid cycle, δOAT—ornithine δ-aminotransferase. Created with BioRender.com (accessed on 26 October 2021).
Figure 2The importance of the P5C-proline cycle in cancer metabolism. Metabolism of P5C depended on specific enzymes establish to the P5C-proline cycle. The activity of these enzymes is accompanied by transport of redox equivalents between the mitochondria and the cytosol that determine cellular processes—proliferation, survival, apoptosis, autophagy. The interconversion of P5C and proline changes the NADP+/NADPH ratio in the cell leading to regulation of phosphoribosyl pyrophosphate (PRPP) synthesis and nucleotide synthesis via pentose phosphate pathway. ATP—adenosine triphosphate, FAD—oxidized form of flavin adenine dinucleotide, FADH2—reduced form of flavin adenine dinucleotide, Glu—glutamate, GSAL—L-glutamate-γ-semialdehyde, HIF-1α—hypoxia-inducible factor 1, METC—mitochondrial electron transport chain, MYC—myelocytomatosis oncogene cellular homologue, NAD+—oxidized form of nicotinamide adenine dinucleotide, NADH—reduced form of nicotinamide adenine dinucleotide, NADP+—oxidized form of nicotinamide adenine dinucleotide phosphate, NADPH—reduced form of nicotinamide adenine dinucleotide phosphate, ORN—ornithine, oxPPP—oxidative arm of the pentose phosphate pathway, p53—tumor protein 53, P5C—Δ1-pyrroline-5-carboxylate, P5CDH—P5C dehydrogenase, P5CS—P5C synthase, PAT1—proton-coupled amino acid transporter 1, PI3K—phosphoinositide 3-kinase, PRODH/POX—proline dehydrogenase/oxidase, PROT—L-proline transporter PROT, PYCR1/2/L—P5C reductase 1/2/L, PPARγ—peroxisome proliferator-activated receptor gamma, ROS—reactive oxygen species, SIT1—sodium/imino-acid transporter 1, SNAT1/2—sodium-coupled neutral amino acid transporter 1/2, TCA cycle—tricarboxylic acid cycle, VEGF—vascular endothelial growth factor, α-KG—α-ketoglutarate, δOAT—ornithine δ-aminotransferase, G-6-P—glucose-6-phosphate, 6-PG—6-phosphogluconate, Ru-5-P—ribulose-5-phosphate, R-5-P—ribose-5-phosphate, PRPP—phosphoribosyl pyrophosphate, 1—glucose-6-phosphate dehydrogenase (G6PDH), 2—6-phosphogluconate dehydrogenase (6PGD). Created with BioRender.com (accessed on 26 October 2021).